Methods for treatment of cancers with EGFR activating mutations

A technique of cancer, chemotherapy, applied in the fields of cancer biology and medicine

Pending Publication Date: 2020-10-30
BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF43 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Identifying effective therapeutic options against cancers that are resistant to TKIs (e.g., T790M-negative resistance) remains a major clinical challenge

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treatment of cancers with EGFR activating mutations
  • Methods for treatment of cancers with EGFR activating mutations
  • Methods for treatment of cancers with EGFR activating mutations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0129] Example 1 - Identification of Methods for Treating Cancers with EGFR Activating Mutations

[0130] Although patients with EGFR-mutant NSCLC initially responded to EGFR-targeted therapy, resistant disease inevitably developed, and in nearly half of the resistant cases, the tumor lacked a secondary EGFR mutation (e.g., T790M), and for the first Second- and third-generation EGFR tyrosine kinase inhibitors (TKIs) are refractory. Identifying effective therapeutic options for T790M-negative resistance remains a major clinical challenge. To address this unmet need, a panel of NSCLC cell lines with acquired resistance to the EGFR TKIs erlotinib, gefitinib, osimertinib or poziotinib was derived.

[0131] For markers of epithelial-to-mesenchymal transition (EMT), the proteomic analysis of resistant cells was performed by reverse phase protein array (RPPA) and Western blot analysis. Drug screening using the Cell Titer glow assay in a high-throughput 384-well plate system. Long-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure provides methods for treating cancer in a patient determined to have an EGFR activating mutation by administering a CDK inhibitor and / or SAC component inhibitor.

Description

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 642,472, filed March 13, 2018, which is hereby incorporated by reference in its entirety. [0002] background [0003] This invention was made with government support under Grant No. CA190628 awarded by the National Institutes of Health. The government has certain rights in this invention. [0004] 1. Technical field [0005] The present invention relates generally to the fields of cancer biology and medicine. More particularly, it relates to methods for treating cancers with EGFR activating mutations. [0006] 2. Background technology [0007] Although patients with EGFR-mutant NSCLC initially respond to EGFR-targeted therapy, resistant disease inevitably develops. In nearly half of the resistant cases, the tumor lacked a secondary EGFR mutation (eg, T790M) and was refractory to second- and third-generation EGFR tyrosine kinase inhibitors (TKIs). Identifying effective treatment optio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/44A61K38/17A61K31/4709
CPCA61K31/44A61K31/4709A61K45/06A61K31/519A61K31/55C12Q1/6886C12Q2600/156C12Q2600/106A61K31/453A61K31/52A61K31/506A61K31/517A61P35/00C12Q1/686C12Q1/6869
Inventor 约翰·V·海马赫莫妮克·尼尔松雅克利内·罗比绍
Owner BOARD OF RGT THE UNIV OF TEXAS SYST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap